Explaining, at least partially, the molecular mechanisms leading to reduced vascular response in Dll4 overexpressing vs. control tumors, these findings also point out the potential capacity of endothelial Dll4 overexpression to increase the efficacy of currently available VEGF signaling-inhibitors whose clinical success has been limited by development of tumor-resistance. The gene discussed is DLL4; the disease is neoplasm.